Shanghai Pharmaceuticals Holding(601607.SH): The sustained-release tablets of bromopride have been approved for production.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary Shanghai Pharmaceuticals Western & Eastern Pharmaceutical Co., Ltd. (referred to as "Shanghai Pharmaceuticals Western & Eastern") has received the "Drug Registration Certificate" (Certificate Number: 2025S03175) issued by the National Medical Products Administration for its bupupamine sustained-release tablets. The drug has been approved for production. Bupupamine sustained-release tablets can be used to treat myasthenia gravis and were originally developed by BAUSCH company, and were first marketed in the United States in 1959. In March 2024, Shanghai Pharmaceuticals Western & Eastern submitted an application for registration and listing of the drug to the National Medical Products Administration, which was accepted. As of the date of the announcement, the company has invested approximately RMB 16.09 million in research and development expenses for this drug. As of the date of this announcement, there are no other companies in China that have listed bupupamine sustained-release tablets.